Aytu Biopharma Inc. Publishes Corporate Presentation Highlighting Focus on CNS Therapeutics and Strategic Growth Initiatives

Aytu Biopharma Inc. has published a corporate presentation detailing its strategic focus on CNS therapeutics, particularly in major depressive disorder and ADHD. The company reported a $34.7 million improvement in adjusted EBITDA over four years due to its new business strategy. Key initiatives include an exclusive agreement for EXXUA™ commercialization, refinancing a term loan, divesting the consumer health business, and outsourcing manufacturing. The Aytu RxConnect platform enhances patient access to prescription products, with over 85% of core brands dispensed through partner pharmacies, improving medication adherence and reducing costs for patients.